QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IRWD

QT75Ironwood Pharmaceuticals, Inc.
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
3.54
+0.02+0.57%
OverviewShort InterestFilings
IRWDQT75Ironwood Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
3.54+0.57%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E5.63EPS (ttm)
0.60
Insider Own-
Shs Outstand-
Perf Week-2.48%
Market Cap579.44MForward P/E2.87EPS next Y1.24Insider Trans-Shs Float-Perf Month-3.54%
Enterprise Value956.32MPEG0.00EPS next Q0.26Inst Own-Short Float-Perf Quarter9.60%
Income102.91MP/S1.60EPS this Y96.67%Inst Trans-Short Ratio-Perf Half Y0.00%
Sales361.52MP/B-EPS next Y4.66%ROA23.51%Short Interest-Perf YTD5.04%
Book/sh-P/C5.13EPS next 5Y-27.84%ROE-38.88%52W High5.78 -38.75%Perf Year457.83%
Cash/sh-P/FCF5.16EPS past 3/5Y-ROIC29.96%52W Low0.62 470.97%Perf 3Y-
Dividend Est.-EV/EBITDA4.62Sales past 3/5Y-10.36% -5.37%Gross Margin99.62%Volatility2.76% 3.98%Perf 5Y-
Dividend TTM-EV/Sales2.65EPS Y/Y TTM10990.91%Oper. Margin55.83%ATR (14)0.22Perf 10Y-
Dividend Ex-Date-Quick Ratio1.41Sales Y/Y TTM3.13%Profit Margin28.26%RSI (14)47.05Recom2.33
Dividend Gr. 3/5Y-Current Ratio1.41EPS Q/Q271.43%SMA200.01%Beta2.20Target Price4.80
Payout0.00%Debt/Eq-2.75Sales Q/Q160.98%SMA50-8.27%Rel Volume2.17Prev Close3.52
Employees253LT Debt/Eq-1.51EarningsAug 06SMA2008.44%Avg Volume2.28MPrice3.54
IPO DateFeb 03, 2010Option/ShortYes / YesEPS/Sales Surpr.242.86% 16.30%Net Debt/EBITDA1.82Volume4,931,666Change0.57%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-26-26ReiteratedJefferiesHold$3.70
Jan-05-26ReiteratedCraig-HallumBuy$3.80 → $5.70
Jan-05-26UpgradeCitizensMarket Perform → Market Outperform
Nov-26-25ReiteratedCraig-HallumBuy$1.70 → $3.80
Apr-15-25DowngradeWells FargoOverweight → Equal Weight
Apr-15-25DowngradeJefferiesBuy → Hold
Apr-14-25ReiteratedLeerink PartnersMarket Perform$5.00 → $1.00
Jan-31-25ReiteratedWells FargoOverweight$12 → $7.00
Sep-09-24InitiatedLeerinkMarket Perform$5.00
Aug-09-24ReiteratedWells FargoOverweight$14 → $12
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue362296351
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A008
Gross Profit361296344
Selling, General and Administrative Excl. Other70820
Research and Development8895111
Other Operating Expense10140
Operating Income20311993
Interest Expense333333
Unusual Expense
———
Non-Operating Income (Expense)-416-3
Net Income Before Taxes1717065
Income Taxes694664
Consolidated Net Income103241
Net Income From Continuing Operations103241
Net Income103241
EPS (Recurring)0.640.150.01
EPS (Basic, Before Extraordinaries)0.640.150.01
EPS (Diluted)0.600.150.01
EBITDA20810598
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio5.9022.47—
Price To Sales Ratio1.591.84—
Gross Margin99.72100.0098.01
Operating Margin56.0840.2026.50
Net Margin28.458.110.28
Shares Outstanding163162159
Market Capitalization577546—
Operating Lease Expense
———
Insider Trading Volume
$3.73$3.33$2.93$2.54$2.14● Close Price0.00M5.13M10.27M15.40M20.53MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
McHugh JulieDirectorJun 16 '26Sale3.7321,57180,460250,749Jun 17 12:00 AM
DENNER ALEXANDER JDirectorMar 17 '26Sale3.056,730,80020,530,4489,188,635Mar 17 12:00 AM
MCCOURT Thomas AChief Executive OfficerFeb 24 '26Sale3.66103,526378,9051,489,002Feb 25 12:00 AM
Silver RonaldPrincipal Accounting OfficerFeb 24 '26Sale3.6612,62146,193252,636Feb 25 12:00 AM
John MinardoChief Legal OfficerFeb 24 '26Sale3.6619,05369,734363,886Feb 25 12:00 AM
Martini Gregory S.Chief Financial OfficerFeb 24 '26Sale3.6611,45741,933160,601Feb 25 12:00 AM
Shetzline MichaelSVP, CMO, Head-Res&DrugFeb 24 '26Sale3.6617,01262,264521,425Feb 25 12:00 AM
Gaskins Tammi LChief Commercial OfficerFeb 24 '26Sale3.6611,23941,135213,738Feb 25 12:00 AM
Silver RonaldPrincipal Accounting OfficerFeb 23 '26Sale3.8111,55244,013265,257Feb 25 12:00 AM
John MinardoChief Legal OfficerFeb 23 '26Sale3.8117,43966,443382,939Feb 25 12:00 AM
Shetzline MichaelSVP, CMO, Head-Res&DrugFeb 23 '26Sale3.8115,57059,322538,437Feb 25 12:00 AM
Gaskins Tammi LChief Commercial OfficerFeb 23 '26Sale3.8110,28739,193224,977Feb 25 12:00 AM
MCCOURT Thomas AChief Executive OfficerFeb 23 '26Sale3.8194,757361,0241,592,528Feb 25 12:00 AM
Martini Gregory S.Chief Financial OfficerFeb 23 '26Sale3.8110,48739,955172,058Feb 25 12:00 AM
Silver RonaldPrincipal Accounting OfficerJan 05 '26Sale4.6035,416162,914276,809Jan 07 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR